Migraine-Attack-Data-Analyses-using-SAS

Comprehensive analysis of patient demographics, clinical assessments, laboratory tests, and summaries of patient data.

1. Summary of Patient Demographics Data:

Demographics of Patients

Table 1. Average Age of Patients by Gender

Gender	N	Mean Age
F	12	31.25
M	8	38.00

Analysis of Smoking and Alcohol

Table 2. Analysis of Smoking and Alcohol

	Smoking	Alcohol
N	16	17
Y	4	3

Analysis of Smoking History and Alcohol Consumption

Table 3. Analysis of Smoking History and Alcohol Consumption

Label	N	Mean	Std Dev
No. of Cigars smoked	30	7.87	1.74
No. of years smoked	30	10.60	3.84
No. of Drinks per week	24	3.42	0.50

Insights:

1. Female patients experiencing migraine attacks tend to have a lower average age than male patients.
2. A considerable portion of migraine patients report both smoking and alcohol consumption, indicating potential lifestyle factors influencing migraine occurrence.
3. Migraine sufferers have smoked an average of 7.87 cigars over a mean duration of 10.60 years, reflecting a notable smoking history among this population.

2. Clinical Examination Analysis

Visit 1

Analysis of Clinical Examination

Table 4. Means of Blood Pressure and Pulse Rate

Label	N	Mean	Std Dev
Pulse	20	75.40	5.32
Systolic Blood Pressure	20	122.20	10.68
Diastolic Blood Pressure	20	75.80	7.81

Table 5. Summary of Other Diseases

Label	N	Percent
Cardio
NAD	18	90.00
NS	1	5.00
S1S2N	1	5.00
Respiratory
Clear NVBS	1	5.00
NAD	19	95.00
Abdomen
Liver Palpable	1	5.00
NAD	17	85.00
Soft and no mass felt	1	5.00
Soft and non tada	1	5.00
Central Nervous System
Clinically N	1	5.00
NAD	19	95.00

Note: No patients were found with Angina, Myoinfa, Allergy and Cerinc.

Insights:

1. The majority of patients have normal pulse rate, systolic blood pressure (SBP), and diastolic blood pressure (DBP) with the following statistics:

   a. Pulse Rate: Mean of 75.40 beats per minute, standard deviation of 5.32.

   b. Systolic Blood Pressure (SBP): Mean of 122.20 mmHg, standard deviation of 10.68.

   c. Diastolic Blood Pressure (DBP): Mean of 75.80 mmHg, standard deviation of 7.81.

2. Most of the patients show no significant abnormalities in their cardiovascular, respiratory, abdominal, and central nervous systems.

3. A small percentage of patients exhibit minor issues.

3. Lab Testing Data Analysis

Lab Testing

Table 6. Analysis of Patient Blood History Data

Label	N	Mean	Std
SC	20	0.72	0.11
Hemoglobin	19	12.34	1.21
Urea	20	17.56	11.08
White Blood Cells	17	10,670.59	1,382.37
Sodium	13	124.38	7.87
Neutrophils	20	68.85	3.66
Eosinophils	11	4.18	7.63
Basophils	4	0.50	0.58
Potassium	13	4.47	0.32
Lymphocytes	20	27.05	7.21
Sugar	20	111.70	26.32
Monocytes	17	1.94	0.75
Platelets	20	2.22	0.56
SB	20	0.76	0.11
SGOT	20	26.40	17.37
SGPT	20	27.65	22.91

Table 7. Summary of Urine Analysis, Pregnancy, and ECG

Label	N	Percent
Urine Analysis
Normal	1	6.67
NAD	12	80.00
Within Normal Limits	2	13.33
Pregnancy
Not Applicable	5	33.33
Negative	10	66.67
ECG
Clinically N	1	6.67
NAD	1	6.67
Normal	1	6.67
Within Normal Limits	12	80.00

Migraine Attack

Table 8. Averages of Time Since Initial Attack (Month), Frequency, and Duration

Label	N	Mean	Std Dev
Time Since Initial Attack (Months)	15	108.60	88.11
Frequency Of Attack In A Month	20	5.50	5.50
Duration Of Attack (Hours)	20	171.00	252.52

Table 9. Analysis of Side Effects Due to Migraine Attack

Label	N	Percent
Aura
N	13	65.00
Y	7	35.00
Nausea
N	4	20.00
Y	16	80.00
Blurred Vision
N	14	70.00
Y	6	30.00
Photophobia
N	10	50.00
Y	10	50.00
Phonophobia
N	6	30.00
Y	14	70.00

Table 10. Analysis of Patient History based on Drug Intake for Migraine

Drug Condition	Drug	Generic	Dose	Continued	Dose	Discontinuation	Duration
migraine	flenarin		1T1D	N		30 days	180 days
migraine			1BD	N		30 days	180 days
migraine	sinarest		1 Tab	N		7 days	60 days
migraine	sumo		1 Tab	N		7 days	60 days
migraine	clotan		200 mg	N		3 days	60 days
migraine	diclofenac		50 mg bd	Y	100 per day		365 days
migraine	paracetamol		650 mg	N		14 days	180 days
migraine	ibuprofen		400 mg	N		14 days	365 days
migraine	sibelium	flunarazine	10 mg OD	N		7 days	30 days
migraine	indual	proprawl 40 mg	40 mg OD	N		7 days	30 days
migraine	proxyron			N			SOS
migraine	suminat	sundriptan	50 mg OD	N		2 days	1 day
migraine
migraine	AMT 25	amytrypliline	25 mg	N		3 days	7 days
migraine	Dolo	paracetamol	650 mg	N		1 day	SOS
migraine	proxyron			N
migraine	sibdlium	flunorozine		N
migraine	brufen	ibuprofen	400				SOS
migraine	vasograin	ergotamine caffeine paracetamol	1 Tab	Y	1 tab per attack		2190 days
migraine	sibellium			N		2 days	30 days
migraine	dolopar			N		7 days	on and off
migraine	sumo	paracetamol and nimesulide	N		7 days	365 days on & off
migraine	indenal	proprawl	40 mg	N		7 days	3 days
migraine	sibellium	flunorozine	10 mg	N		7 days	3 days
migraine	duodil			N		7 days	3 days
migraine
migraine	dolo	paracetamol	650 mg	N		30 days	180 days
migraine	crocin	paracetamol	500 mg	N		15 days	90 days
migraine	flurazine			N		14 days	180 days
migraine	dolo	paracetamol	650 mg	N		14 days	180 days

Table 11. Analysis of Patient History based on Drug Intake for other than Migraine

Drug Condition	Drug	Generic	Dose	Continued	Dose	Discontinuation	Duration
others	neupro		20 mg BD	N		180 days	7 days
others	theoasthalin		on and off				9125 days
others	asthalin inhaler						3650 days

Insights:

1. Diclofenac (50 mg bd) is frequently used for managing migraines, with some patients taking it for up to 365 days.
2. Other commonly used medications include paracetamol (650 mg) and ibuprofen (400 mg), often taken as needed (SOS) or for short durations (7-14 days).
3. The extensive use of various medications underscores the necessity for personalized treatment plans to manage migraine symptoms effectively.
4. For non-migraine conditions, patients often use medications like theoasthalin intermittently over extended periods (up to 9125 days), indicating the chronic management of respiratory conditions.
5. Asthalin inhalers are also used long-term (up to 3650 days), highlighting the need for sustained treatment in certain chronic conditions.

4. Summary of Patient Status

Table 22. Analysis of Functional Capability and Global Evaluation

Label	N	Percent
Functional Disability
0	14	70.00
1	2	10.00
2	4	20.00
Patient Global Evaluation
excellent	9	45.00
good	5	25.00
poor	2	10.00
satisfactory	4	20.00
Investigation Global Evaluation
effective	4	20.00
not effective	5	25.00
very effective	11	55.00
Patient Study Status
Y	20	100.00

Insights:

Functional Disability:

70% of patients reported no functional disability (score 0), indicating a high level of functionality despite their condition. 10% of patients had a mild functional disability (score 1). 20% of patients experienced moderate functional disability (score 2).

Patient Global Evaluation:

45% of patients rated their overall condition as excellent, suggesting effective management or mild severity of their symptoms. 25% of patients rated their condition as good, indicating satisfactory control over their symptoms. 20% of patients rated their condition as satisfactory, while 10% rated it as poor, highlighting that a minority of patients still struggle with significant issues.

Investigation Global Evaluation:

55% of patients found their treatment to be very effective, showing a majority benefit significantly from their current treatment plans. 20% of patients rated their treatment as effective. 25% of patients found their treatment not effective, indicating a need for alternative approaches or further investigation. Patient Study Status:

All patients (100%) were fully compliant and involved in the study (status Y), ensuring the reliability and completeness of the data collected.

*******************************************************;